New Franco-Italian biotech park
A new cross-border biotechnology park has been set up at Archamps in the Haute-Savoie region of France to focus on diseases of aging and health care issues related to longevity and wellbeing.
The biotechnology platform links French and Italian research laboratories and extensive animal testing facilities based on a range of models of aging. The Rhone-Alpes Futur Foundation, which is responsible for seven regional research sites, will manage technical personnel at the site and will integrate Archamps in the main regional biotechnology R&D networks, such as Genopole and the new transalpine Biocluster created by BioAlps in French-speaking Switzerland, Adebag in the Grenoble area and the Italian BioIndustry Park in Turin and the Piedmont region.
Five major projects are in hand in the areas of immunology and the process of fragilization and age, and the center will work on regenerative medical projects to develop new therapies for the treatment of Alzheimer's and on hormonal regeneration in the nervous system.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze